top of page

Chairman Experimental Pharmacology & Dean of Studies

European Center for Angioscience,

Medical Faculty Mannheim, Heidelberg University


Thomas Wieland obtained his PhD in Pharmacology and his state doctorate in the laboratory of Karl H. Jakobs at Heidelberg University and the University of Duisburg - Essen, respectively. He pursued his postdoctoral training at Heidelberg University and the University of Duisburg - Essen before he received full professorship at the University of Hamburg and Heidelberg University. Currently, he is Chairman of Experimental Pharmacology and Dean of Studies.

Qualifications and Scientific Curriculum







Studies in Pharmacy, Heidelberg University, Germany

Graduate Studies in Pharmacology, Heidelberg University, Germany

PhD in Pharmacology

State doctorate in Pharmacology and Toxicology, University of Duisburg - Essen, Germany

Postdoctoral Scholar, Department of Pharmacology, Heidelberg University, Germany

Postdoctoral Scholar, Department of Pharmacology, University of Duisburg - Essen, Germany,

Full Professor, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Hamburg, Germany

Full Professor, Institute of Experimental and Clinical Pharmacology and Toxicology, Heidelberg University, Germany

Dean of Studies, Mannheim Medical Faculty, Heidelberg University, Germany


since 2002

since 2015

Selected publications

  1. Felix I, Lomada SK, Barth H, Wieland T: Bacillus anthracis' PA63 Delivers the Tumor Metastasis Suppressor Protein NDPK-A/NME1 into Breast Cancer Cells. Int J Mol Sci, 21:3295, 2020.

  2. Abu-Taha IH, Heijman J, Feng Y, Vettel C, Dobrev D, Wieland T: Regulation of heterotrimeric G-protein signaling by NDPK/NME proteins and caveolins: an update. Lab Invest, 98:190-197, 2018.

  3. Garg J, Feng YX, Jansen SR, Friedrich J, Lezoualc'h F, Schmidt M, Wieland T: Catecholamines facilitate VEGF-dependent angiogenesis via β2-adrenoceptor-induced Epac1 and PKA activation. Oncotarget, 8:44732-44748, 2017.

  4. Abu-Taha IH, Heijman J, Hippe HJ, Wolf NM, El-Armouche A, Nikolaev VO, Schäfer M, Würtz C, Neef S, Voigt N, Baczkó I, Varró A, Müller M, Meder B, Katus, HA, Spiger K, Vettel C, Lehmann LH, Backs J, Skolnik EY, Lutz S, Dobrev D, Wieland T: Nucleoside Diphosphate Kinase-C Suppresses cAMP Formation in Human Heart Failure. Circulation, 135:881-97, 2017.

  5. Zhou XB, Feng YX, Sun Q, Lukowski R, Qiu Y, Spiger K, Li Z, Ruth P, Korth M, Skolnik EY, Borggrefe M, Dobrev D, Wieland T: Nucleoside diphosphate kinase B-activated intermediate conductance potassium channels are critical for neointima formation in mouse carotid arteries. Arterioscler Thromb Vasc Biol, 35:1852-61, 2015.

  6. Feng Y, Gross S, Wolf NM, Butenschön VM, Qiu Y, Devraj K, Liebner S, Kroll J, Skolnik EY, Hammes HP, Wieland T: Nucleoside diphosphate kinase B regulates angiogenesis through modulation of vascular endothelial growth factor receptor type 2 and endothelial adherens junction proteins. Arterioscler Thromb Vasc Biol, 34:2292-300, 2014.

  7. Hippe HJ, Wolf NM, Abu-Taha I, Mehringer R, Just S, Lutz S, Niroomand F, Postel EH, Katus HA, Rottbauer W, Wieland T: The interaction of nucleoside diphosphate kinase B with Gbg dimers controls heterotrimeric G protein function. Proc Natl Acad Sci U S A, 106:16269-74, 2009.

  8. Hippe HJ, Luedde M, Lutz S, Koehler H, Eschenhagen T, Frey N, Katus HA, Niroomand F, Wieland T: Regulation of cardiac cAMP synthesis and contractility by nucleoside diphosphate kinase B/G protein bg dimer complexes. Circ Res, 100:1191-9, 2007.

  9. Lutz S, Shankaranarayanan A, Coco C, Ridilla M, Nance MR, Vettel C, Baltus D, Evelyn CR, Neubig RR, Wieland T, Tesmer JJ: Structure of Gaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science, 318:1923-7, 2007.

  10. Lutz S, Freichel-Blomquist A, Yang Y, Rümenapp U, Jakobs KH, Schmidt M, Wieland T: The guanine nucleotide exchange factor p63RhoGEF, a specific link between Gq/11-coupled receptor signaling and RhoA. J Biol Chem, 280:11134-9, 2005.

bottom of page